Search results
Results From The WOW.Com Content Network
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8 ]
Nephrotoxicity is toxicity in the kidneys. It is a poisonous effect of some substances , both toxic chemicals and medications , on kidney function . [ 1 ] There are various forms, [ 2 ] and some drugs may affect kidney function in more than one way.
Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]
Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4]
Meaning, quickly fixing blood sugar issues that patient may have had could have a big impact on their vision health. This isn’t a new thing, says Christoph Buettner, M.D., ...
Kidney ischemia [1] is a disease with a high morbidity and mortality rate. [2] Blood vessels shrink and undergo apoptosis which results in poor blood flow in the kidneys. More complications happen when failure of the kidney functions result in toxicity in various parts of the body which may cause septic shock, hypovolemia, and a need for surgery. [3]
Extra pounds mean accumulated fat in your liver, which silently inflames it and can lead to liver failure. About 44 percent of men already have Metabolic Dysfunction-Associated Steatotic Liver ...
That said, Vanessa Rissetto, R.D., co-founder of the virtual nutrition care service Culina Health, believes the FDA's move is a positive step forward."Early-stage cancers are on the rise across ...